Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 32Unknown 4Withdrawn 3Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 26Lymphoma, Large B-Cell, Diffuse 19Burkitt Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, T-Cell, Peripheral 8Lymphoma, Follicular 8Lymphoma, B-Cell 7Lymphoma 7Neoplasms 5Lymphoma, Non-Hodgkin 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Leukemia, Biphenotypic, Acute 3Recurrence 2Prostatic Neoplasms, Castration-Resistant 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Ovarian Neoplasms 2Myasthenia Gravis 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1

Interventions

Rituximab 20zanubrutinib 13acalabrutinib 11Magnetic Resonance Spectroscopy 11obinutuzumab 10Specimen Handling 10Cyclophosphamide 10Biopsy 9glofitamab 8Bendamustine Hydrochloride 8pirtobrutinib 7fludarabine 7venetoclax 6orelabrutinib 6ibrutinib 5Lenalidomide 5Cytarabine 5fludarabine phosphate 3Immunotherapy, Adoptive 3CT-P10 3tafasitamab 2polatuzumab vedotin 2loncastuximab tesirine 2brexucabtagene autoleucel 2Whole-Body Irradiation 2Therapeutics 2Prednisone 2Melphalan 2Maintenance 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Mantle-Cell × Prednisone × Clear all
NCT06564038 2026-05-14

Soundtrack-E

AstraZeneca

Phase 1/2 Recruiting
408 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04626791 2024-03-12

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Academic and Community Cancer Research United

Phase 2 Recruiting
45 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡